Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.jpba.2012.09.027
Title: | Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic study | Authors: | Lin, H.-S. Sviripa, V.M. Watt, D.S. Liu, C. Xiang, T.-X. Anderson, B.D. Ong, P.S. Ho, P.C. |
Keywords: | Absolute oral bioavailability Dose-escalation HPLC Pharmacokinetics Trans-2,6-Difluoro-4'-N,N-dimethylaminostilbene |
Issue Date: | 18-Jan-2013 | Citation: | Lin, H.-S., Sviripa, V.M., Watt, D.S., Liu, C., Xiang, T.-X., Anderson, B.D., Ong, P.S., Ho, P.C. (2013-01-18). Quantification of trans-2,6-difluoro-4'-N,N-dimethylaminostilbene in rat plasma: Application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis 72 : 115-120. ScholarBank@NUS Repository. https://doi.org/10.1016/j.jpba.2012.09.027 | Abstract: | trans-2,6-Difluoro-4'-N,N-dimethylaminostilbene (DFS), a synthetic stilbene, displayed potent pre-clinical anti-cancer activities exceeding that observed for naturally occurring resveratrol. In this study, a simple and sensitive HPLC method was developed and validated to quantify DFS in rat plasma. The lower limit of quantification (LLOQ) was 5ng/ml. The intra- and inter-day variation in terms of relative standard deviation (RSD) was all less than 10%. The bias rate ranged from -11.5% to 6.2% while the absolute recovery ranged from 94.1±2.3 to 97.3±4.4%. The pharmacokinetic profiles of DFS were examined in Sprague-Dawley rats after intravenous administration (2 mg/kg). DFS displayed moderate clearance (Cl=61.5±17.7ml/min/kg) and a relatively prolonged terminal elimination half-life (t1/2 λz) of 351±180min. Aqueous solubility played a crucial role in the oral absorption of DFS. When DFS was given as a suspension (6mg/kg), the absolute oral bioavailability (F) was almost negligible. However, when DFS was given in a solution prepared with hydroxypropyl-β-cyclodextrin (6mg/kg), the F was 12.4±10.7%. Dose-escalation to 15mg/kg resulted in much higher systemic exposure (F=40.2±10.0%). As DFS is orally available after formulation with hydroxypropyl-β-cyclodextrin and pharmacologically active systemic concentrations could be achieved after a single oral dose, the use of DFS as a cancer chemopreventive/chemotherapeutic agent is possible. © 2012 Elsevier B.V. | Source Title: | Journal of Pharmaceutical and Biomedical Analysis | URI: | http://scholarbank.nus.edu.sg/handle/10635/106279 | ISSN: | 07317085 | DOI: | 10.1016/j.jpba.2012.09.027 |
Appears in Collections: | Staff Publications |
Show full item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.